Daiichi Sankyo sold its consumer health unit to Suntory Holdings for 246.5 billion yen, roughly $1.55 billion, in a staged transfer that kicks off this June with 30% of shares changing hands.
The deal covers Daiichi Sankyo Healthcare, which markets Lulu, a decades-old combination cold remedy, and Loxonin, an anti-inflammatory pain and fever reducer, along with a broader range of skincare, oral care, and food products. Suntory gets a consumer OTC portfolio anchored by decades-old brands; what it’s worth at $1.55 billion for a unit with beverage-adjacent categories is a question the drinks company has clearly worked through.
The closest comp is Sanofi’s Opella deal. The French pharma giant pulled in 10 billion euros last spring by selling a controlling stake in its consumer health business to Clayton, Dubilier & Rice. Daiichi’s exit at $1.55 billion covers a smaller, Japan-focused business, but the strategic logic is identical: fund the drug pipeline by monetizing slow-growth OTC assets.
For Daiichi, the calculus isn’t complicated. The company’s two AstraZeneca-partnered ADCs: Enhertu is cleared across breast, gastric, NSCLC, and HER2-positive solid tumors; Datroway covers certain breast cancer and NSCLC patients. At J.P. Morgan earlier this year, CEO Hiroyuki Okuzawa said he wants ADCs covering 700,000 eligible patients by fiscal year 2030, up from 120,000 in FY2025. Selling Lulu to fund that trajectory makes sense.
The full transfer wraps by June 2029.
Diana Kowalski